Recombinant Sendai virus provides a highly efficient gene transfer into human cord blood-derived hematopoietic stem cells

Induction of Efficient Antitumor Immunity Using Dendritic Cells Activated by Recombinant Sendai Virus and Its Modulation by Exogenous IFN-β Gene

“…Elimination of CD4 ϩ or CD8 ϩ cells in tumor-bearing mice (n ϭ 4 -5 in each group) was done by i.p. injection of mAbs on days 5,6,7,10,13,16,19,21,24,27, and 30 after the primary tumor inoculation. Flow cytometry confirmed Ͼ98% depletion of the target cells for at least 7 days after injection in all animals.…”

“…Furthermore, there are technical advantages in the use of rSeV as a gene therapy vector; first, the infectious activity of SeV particles is stable to be easily concentrated to high titers by ultracentrifugation, which is in clear contrast to the features of retroviral vectors. Second, and most importantly, the modalities of target cell processing and viral transduction are technically nondemanding and feasible in clinical situations that require transduction into large numbers of target cells, including hemopoietic stem cells (16). Despite these advantageous features of SeV in clinical gene therapy strategies over the other vector systems (10 -12), the related immune responses due to virus administration in vivo have been hazardous to expand the use of this mode of vector in the clinical setting, similar to other viral vectors including adenoviruses.…”

Genetic modification of hematopoietic stem cells with nonviral systems: past progress and future prospects

“…172 A recombinant Sendai virus has recently been exploited to achieve highly efficient transfection (85.5%) of cord blood CD34 + cells without cytokine prestimulation. 173 Mitotic stability of pDNA in the nucleus Mitotic stability of plasmid DNA can be achieved either through episomal maintenance or through chromosomal integration by the use of transposon 174 or phage integrase. 175,176 Episomal maintenance is the most ambitious goal concerning stable gene transfer.…”

Recombinant Sendai virus vectors for activated T lymphocytes

“…Moreover, optimal SeV-mediated gene transfer to activated T cells could be performed during a relatively brief exposure time (less than 30 min, Figure 4d), with representative results seen in nasal mucosa, 20 in the vasculature, 21 in retinal tissue, 24 as well as in human umbilical cord bloodderived CD34-positive cells. 45 In addition, rare syncytium formation and few cytopathic effects were observed at the MOI used in this study (data not shown). Furthermore, changes in the number of activated T cells that were cocultured with SeV-EGFP were comparable to those observed in activated T cells cultured without SeV (data not shown).…”